EFS as GF-GVHD II-IV–free survival. (A) Patients receiving a graft from MSD were significantly superior in EFS (P = .003). In direct comparison of MSD and 10/10 MD we also observed a significant superiority in EFS for MSD (P = .011). (B) Patients receiving an allo-HSCT during infancy (<13 months) showed a significantly better EFS compared to older patients (P = .004). (C) EFS was also significantly higher in patients having a donor with a matching CMV serology status (+/+ or −/−) (P < .001).